title: Serum level of osteopontin as a prognostic factor in patients who underwent surgical resection for non-small-cell lung cancer.
abstract: BACKGROUND
  OPN is a multifunctional glycophosphoprotein originally described as a secreted protein from malignant epithelial cells. This study focused on the clinical significance of preoperative serum level of OPN in NSCLC patients who underwent a complete resection.
  
  
  METHODS
  The serum OPN level was assayed in 244 patients who underwent a complete resection of NSCLC by commercially available sandwich enzyme-linked immunosorbent assay kits. The patients were considered as a higher group, when the serum OPN levels exceeded 81.3 ng/mL.
  
  
  RESULTS
  The patients included 166 male and 78 female subjects. The histologic types included 172 adenocarcinomas, 49 squamous cell carcinomas, and 23 other types of carcinoma. The serum level of OPN in male patients (92.6 ng/mL) was significantly higher than that of female patients (76.9 ng/mL). The OPN level of squamous cell carcinoma was significantly higher than that of adenocarcinoma. The OPN level was significantly elevated in patients with the pleural invasion or microvascular invasion than those without the invasion. The 5-year survival rate after surgery in the lower OPN group (82.0%) was a significant favorable prognosis than that in the higher OPN group (63.7%) (P < .0001). The 5-year survival rates in the lower OPN group at stage I NSCLC (88.1%) was significantly better than that in the higher OPN group (80.5%) (P = .0321).
  
  
  CONCLUSIONS
  The preoperative serum OPN level was a useful predictor of an unfavorable prognosis, and it was found to be an independent prognostic determinant of outcome in patients who underwent surgery for NSCLC.
authors.affiliation: Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan.
authors.forename: Masaru
authors.initials: M
authors.lastname: Takenaka
authors.forename: Takeshi
authors.initials: T
authors.lastname: Hanagiri
authors.forename: Shinji
authors.initials: S
authors.lastname: Shinohara
authors.forename: Manabu
authors.initials: M
authors.lastname: Yasuda
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Chikaishi
authors.forename: Soich
authors.initials: S
authors.lastname: Oka
authors.forename: Hidehiko
authors.initials: H
authors.lastname: Shimokawa
authors.forename: Yoshika
authors.initials: Y
authors.lastname: Nagata
authors.forename: Makoto
authors.initials: M
authors.lastname: Nakagawa
authors.forename: Hidetaka
authors.initials: H
authors.lastname: Uramoto
authors.forename: Tomoko
authors.initials: T
authors.lastname: So
authors.forename: Sohsuke
authors.initials: S
authors.lastname: Yamada
authors.forename: Fumihiro
authors.initials: F
authors.lastname: Tanaka
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000097:blood*; D002289:Carcinoma, Non-Small-Cell Lung / Q000097:blood* / Q000401:mortality / Q000601:surgery; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008175:Lung Neoplasms / Q000097:blood* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D053495:Osteopontin / Q000097:blood*; D011379:Prognosis; D016016:Proportional Hazards Models; D055815:Young Adult
chemical_list: D014408:Biomarkers, Tumor; D053495:Osteopontin